Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 977-987 , November 2010

Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with 188Re-RC-160

  • Rong Zhao

      Affiliations

    • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
    • ,
  • Weidong Yang

      Affiliations

    • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
    • ,
  • Zhe Wang

      Affiliations

    • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
    • ,
  • Guoquan Li

      Affiliations

    • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
    • ,
  • Weiwei Qin

      Affiliations

    • Laboratory of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
    • ,
  • Jing Wang

      Affiliations

    • Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 029 84775449; fax: +86 029 81230242.

Received 11 April 2010 ,Revised 18 May 2010 ,Accepted 21 May 2010.

References 

  1. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20:255–264
  2. Buchsbaum DJ. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med. 2004;34:32–46
  3. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84–91
  4. Krenning EP, Kwckkeboom DW, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe′]- and [l23I-Tyr′]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  5. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev. 1991;12:450–482
  6. Bakker WH, Kreening EP, Breeman WAP, et al. In vivo use of a radiolabeled somatostatin analog: dynamics, metabolism and binding to somatostatin receptor-positive tumors in man. J Nucl Med. 1991;32:1184–1189
  7. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with In-111-DTPA-D-Phe-l-octreotide in man: metabolism, dosimetry and comparison with I-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–658
  8. Kvols LK, Brown ML, O'Connor MK, et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology. 1993;187:129–133
  9. Fjälling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519
  10. McCarthy KE, Woltering EA, Antony LB. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med. 2000;44:88
  11. Waldherr C, Pless M, Maecke H, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610–616
  12. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–434
  13. Bugaj JE, Erion JL, Johnson MA, Schmidt MA, Srinivasan A. Radiotherapeutic efficacy of 153Sm-CMDTPA-Tyr3-octreotate in tumor-bearing rats. Nucl Med Biol. 2001;28:327–334
  14. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med. 2003;30:417–422
  15. de Jong M, Breeman WA, Bernard BF, et al. [177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628–633
  16. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 1988;48:6977–6985
  17. Zamora PO, Gulhke S, Bender H, et al. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer. 1996;65:214–220
  18. Zamora PO, Bender H, Knapp FFR, Biersack HJ. Regional radiotherapy of intra-thoracic human carcinomas xenografts with 188Re-RC-160, a somatostatin analogue. Tumor Target. 1996;2:49
  19. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198
  20. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 2001;47:30–39
  21. Gambhir SS, Barrio JR, Herschman HR, et al. Assays for noninvasive imaging of reporter gene expression. Nucl Med Boil. 1999;26:481–490
  22. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003;18:601–609
  23. Wang M, Caruano AL, Lewis MR, et al. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res. 2003;63:6864–6869
  24. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658
  25. Munson P, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem. 1980;107:220–239
  26. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52:605–611
  27. Buchegger F, Pfister C, Fournier K, et al. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab′)2 fragments. J Clin Invest. 1989;83:1449–1456
  28. Kwa HB, Verhoeven AHM, Storm J, Vanzandwijk N, Mooi WJ, Hilkens J. Radioimmunotherapy of small cell lung cancer xenografts using iodine-131 -labelled anti-Ncam monoclonal antibody 123c3. Cancer Immunol Immunother. 1995;41:169–174
  29. Buchegger F, Rojas A, Delaloye AB, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res. 1995;55:83–89
  30. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med. 1992;33:1648–1653
  31. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-Cell malignancies with 131-Lym-l. Cancer Res. 1990;50(suppl):1014s–1016s
  32. Vallabhajosula S, Moyer BR, James JL, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med. 1996;37:1016–1022
  33. Gillespie J, Poston GJ, Schachter M, Guilloul PJ. Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer. 1992;66:483–487
  34. Bernard BF, Krenning EP, Breeman WA, et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929–1933
  35. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591–2610
  36. Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology. 2001;142:121–128
  37. Giannetti N, Enjalbert A, Krantic S. Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation. J Cell Biochem. 2000;78:666–673
  38. Lachowicz-Ochedalska A, Rebas E, Kunert-Radek J, Winczyk K, Pawlikowski M. Effects of somatostatin and its analogues on tyrosine kinase activity in rodent tumors. Biol Signals Recept. 2000;9:255–259
  39. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298:1384–1386
  40. Yuan M, Wang J, Deng J, Wang Z, Yang W, Li G, et al. Combination therapy in A549 cells. Nucl Med Biol. 2010;37:317–326
  41. Takahashi M, Sato T, Sagawa T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther. 2002;5:627–634
  42. Rogers BE, Zinn KR, Buchsbaum DJ. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q J Nucl Med. 2000;44(3):208–223
  43. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther. 2001;1(1):101–122
  44. Crystal RG. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol. 1999;43(Suppl):S90–S99

PII: S0969-8051(10)00306-9

doi: 10.1016/j.nucmedbio.2010.05.007

Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 977-987 , November 2010

Article Tools

* Image Usage & Resolution